富马酸依美斯汀治疗慢性荨麻疹的疗效研究  

Study on the efficacy of emedastine difumarate in the treatment of chronic urticaria

作　　者：孙蔚凌 吴国勤 王军[3] SUN Weiling;WU Guoqin;WANG Jun(Department of Dermatology,the First Affiliated Hospital of Nanjing Medical University/Jiangsu Provincial People′s Hospital,Nanjing,Jiangsu 210029,China;Department of Dermatology,Zhongshan Hospital Fudan University,Shanghai 200032,China;Department of Dermatology and Venereology,Yijishan Hospital of Wannan Medical University,Wuhu,Anhui 241001,China)

机构地区：[1]南京医科大学第一附属医院/江苏省人民医院皮肤科,南京210029 [2]复旦大学附属中山医院皮肤科,上海200032 [3]皖南医学院弋矶山医院皮肤性病科,安徽芜湖241001

出　　处：《重庆医学》2021年第4期650-653,共4页Chongqing medicine

摘　　要：目的评价富马酸依美斯汀治疗慢性荨麻疹的有效性和安全性。方法选取2019年7—12月于南京医科大学第一附属医院、复旦大学附属中山医院、皖南医学院弋矶山医院就诊的119例慢性荨麻疹患者为研究对象,分为试验组(n=59)和对照组(n=60)。试验组口服富马酸依美斯汀缓释胶囊2 mg,每日2次;对照组口服氯雷他定片每日10 mg,每日1次,两组连续服药2周,比较两组症状和体征评分总分、总分改善率、临床控制率和总有效率。结果用药后1、2周两组总分下降值和总分改善率比较,差异无统计学意义(P>0.05)。用药前及用药后1、2周两组组内前后比较,差异有统计学意义(P<0.05)。用药后2周同一医院两组间及不同医院相同组间临床控制率和有效率比较,差异无统计学意义(P>0.05)。试验组7例(11.86%)和对照组5例(8.33%)发生不良反应,差异无统计学意义(P>0.05)。结论富马酸依美斯汀治疗慢性荨麻疹疗效及安全性较好。Objective To evaluate the effecacy and safety of emedastine difumarate in the treatment of chronic urticaria.Methods A total of 119 patients with chronic urticaria who attended the First Affiliated Hospital of Nanjing Medical University,Zhongshan Hospital Fudan University and Yijishan Hospital of Wannan Medical College from July to December 2019 were selected and divided into the experiment groups(n=59)and the control group(n=60).The experiment group took 2 mg emedastine difumarate sustained-release capsules twice a day,the control group took loratadine tablets 10 mg daily once a day.The two groups took the drug for 2 weeks continuously.Compared the total scores of symptoms and signs,total score improvement rate,clinical control rate and total effective rate between the two groups.Results There was no statistically significant difference in the total score reduction and the total score improvement rate of the two groups at 1 and 2 weeks after medication(P>0.05).Before and 1,2 weeks after treatment,the difference between the two groups was statistically significant(P<0.05).There was no statistically significant difference in the clinical control rate and effective rate between the two groups in the same hospital and the same group in different hospitals at 2 weeks after treatment(P>0.05).Adverse reactions occurred in 7 cases(11.86%)in the experiment group and 5 cases(8.33%)in the control group,the difference was not statistically significant(P>0.05).Conclusion Emedastine difumarate has good efficacy and safety in the treatment of chronic urticaria.

关 键 词：荨麻疹 富马酸依美斯汀 随机对照试验 氯雷他定 治疗结果 

分 类 号：R765.21[医药卫生—耳鼻咽喉科]